Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Basildon Bond who wrote (461)	5/3/1999 11:35:00 AM
From: Dave Gore	Respond to of 518

THE KEY FOR CELN SHAREHOLDERS: CELN is offering the ONLY effective alternative to painful surgery, in a $8-10 BILLION dollar worldwide market.... ( and really a $30-40 Billion market since only 23% of men are reporting their prostate problem) "A February 1997 PIPER JAFFREY research report on urology estimated the overall costs of BPH therapy in the U.S. at $2.5-3.0 billion annually. In addition, only 23% of an estimated 7.5 million men suffering from BPH are under a doctor's care in the U.S. A December 1996 Dain Bosworth industry report estimated $8-10 billion is spent worldwide in treating BPH, which affects 50 percent of men over age 50." ONLY 23% of men currently seeking help The BPH problem is huge (about 50% of men over 50 worldwide) IN 1996, there were $8-10 BILLION spent There is no other effective relief EXCEPT painful, and long drawn out surgery (and while some serious patients will certainly still need surgery, the CELN alternative for the biggest group of men with moderate problems should be ideal) ** A well respected doctor has been oversseing Phase I testing and Phase II testing is all that is required prior to marketing. FROM THE PR: "Dr. Arnold Melman, [is] the principal investigator of the Phase I studies at the Montefiore Medical Center. He is also professor and chairman of the urology departments at both Montefiore and the Albert Einstein College of Medicine." "'Our studies to date suggest that Celsion's treatment can be performed on an outpatient basis and the preliminary results suggest that the system, when fully tested and approved, could provide immediate symptomatic relief,'' added Dr. Melman. ''If Phase II studies are successful, I believe Celsion's system should encourage a greater number of men with BPH to seek treatment, particularly those who suffer from milder forms of the condition.''